Table 1.
Characteristics of control subjects and patients with rheumatoid arthritis.
| Characteristics | RA | HC |
|---|---|---|
| Number of samples | 21 | 22 |
| Sex, male/female (% women) | 10/11 (52.4) | 11/11 (50) |
| Age, mean ± SD (years) | 60 ± 12.0 | 54.7 ± 6.4 |
| Disease duration (years) | 16.1 ± 13.3 | NA |
| Positive ACPA, n (%) | 21 (100) | NA |
| Positive RF, n (%) | 21 (100) | NA |
| C-reactive protein (mg/L) | 14.1 ± 23.2 | NA |
| DAS28 | 2.6 ± 1.4 | NA |
| ESR | 21.8 ± 18.7 | NA |
| Drug use, n (%) | ||
| Infliximab | 7 (41.2%) | NA |
| Tocilizumab | 5 (29.5%) | NA |
| Rituximab | 5 (29.5%) | NA |
| Adalimumab | 1 (5.4%) | NA |
| Prednisolone | 5 (29.5%) | NA |
| Methotrexate | 7 (41.2%) | NA |
Values are expressed as the mean (±standard errors) for continuous variables or as percentages for categorical variables. Abbreviations: NA: not applicable; RA: Rheumatoid arthritis; HC: healthy controls; ACPA: Antibodies to citrullinated protein antigen; RF: Rheumatoid factor; DAS28: Disease Activity Score-28; ESR: Erythrocyte sedimentation rate.